Novartis’ Tafinlar + Mekinist Receives the US FDA’s Approval for BRAF V600E Low-Grade Glioma in Pediatric Patients
- The US FDA has approved Tafinlar (dabrafenib) + Mekinist (trametinib) for pediatric patients aged ≥1yr. with LGG with a BRAF V600E mutation who requires systemic therapy. The US FDA also approved liquid formulations of Tafinlar and Mekinist
- The approval was based on the results from the P-II/III trial (TADPOLE) trial evaluating Tafinlar + Mekinist (BRAF/MEK inhibitor) vs CT in 149 children and adolescent patients
- The results showed that patients experienced an improvement in ORR of 47% vs 11% and m-PFS was 20.1 vs 7.4mos. at a median follow-up of 18.9mos. The safety profile was consistent with the known safety profile in other approved indications & the results was presented at ASCO 2022
Ref: Novartis| Image: Novartis
Related News:- Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gliomas at ASCO 2022
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].